NASDAQ FNCH opened at $2.15 on Tuesday. The stock has a 50-day moving average price of $4.49. Finch Therapeutics Group has a 52 week low of $2.02 and a 52 week high of $22.10. The company has a market cap of $102.20 million, a PE ratio of -1.11 and a beta of 0.89.
Several large investors have recently modified their holdings of FNCH. BlackRock Inc. raised its holdings in Finch Therapeutics Group by 2.2% during the fourth quarter. BlackRock Inc. now owns 395,782 shares of the company’s stock worth $3,946,000 after purchasing an additional 8,443 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Finch Therapeutics Group in the 4th quarter worth $126,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Finch Therapeutics Group in the fourth quarter valued at $274,000. Citadel Advisors LLC bought a new position in Finch Therapeutics Group during the fourth quarter valued at about $771,000. Finally, State Street Corp grew its holdings in Finch Therapeutics Group by 1.7% during the fourth quarter. State Street Corp now owns 106,219 shares of the company’s stock worth $1,059,000 after acquiring an additional 1,807 shares during the period. 22.68% of the stock is owned by institutional investors.
Finch Therapeutics Group Company Profile (Get Rating)
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.
- Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Follow The Money To Cigna
- Intuitive Surgical is an Intuitive Buy
- The Low In Lordstown Motors May Not Be The Last
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.